Upregulation of PTTG1 is associated with poor prognosis in prostate cancer.

Pituitary tumor-transforming gene 1 (PTTG1) is a regulator of chromosome stability. PTTG1 overexpression had been associated with tumor aggressiveness in several cancer types. To examine its prognostic utility in prostate cancer, a tissue microarray including 12 427 tumors with clinical and molecular data was analyzed by immunohistochemistry. PTTG1 immunostaining was largely absent in normal prostate epithelial cells. In cancers, staining was considered weak in 5.4%, moderate in 5.6% and strong in 0.8%. Strong staining was linked to advanced pT stage, high classical and quantitative Gleason grade, high Ki67-labeling index (all P < 0.0001) and lymph node metastasis (P = 0.0083). The prognostic impact of PTTG1 expression was independent of established preoperative and postoperative prognostic features. Comparison with molecular features revealed that PTTG1 upregulation was associated with nine of 12 common genomic deletions (P < 0.05), p53 alterations and high androgen receptor levels (P < 0.001 each), but was unrelated to the TMPRSS2:ERG fusion status. In conclusion, these data identify PTTG1 as a strong and independent prognostic feature in prostate cancer. PTTG1 measurement, either alone or in combination with other biomarkers might be instrumental for determining prostate cancer aggressiveness. © 2020 The Authors. Pathology International published by Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

Citation

Christoph Fraune, Serhiy Yehorov, Andreas M Luebke, Stefan Steurer, Claudia Hube-Magg, Franziska Büscheck, Doris Höflmayer, Maria Christina Tsourlakis, Till S Clauditz, Ronald Simon, Guido Sauter, Sören Weidemann, David Dum, Simon Kind, Sarah Minner, Thorsten Schlomm, Hartwig Huland, Hans Heinzer, Markus Graefen, Eike Burandt. Upregulation of PTTG1 is associated with poor prognosis in prostate cancer. Pathology international. 2020 Jul;70(7):441-451

Mesh Tags

Substances

PMID: 32314536

search → result